FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
- Thursday, July 6, 2023, 7:02
- Finance
- Add a comment
LEXINGTON, Mass., July 6, 2023 /PRNewswire/ — Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today announced…
About the Author
adminasapcorp has written 41283 stories on this site.